New Zealand markets open in 7 hours

PFE Feb 2023 55.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.74000.0000 (0.00%)
As of 02:48PM EDT. Market open.
Full screen
Previous close1.7400
Open1.8000
Bid1.9200
Ask1.9800
Strike55.00
Expiry date2023-02-17
Day's range1.7200 - 1.9100
Contract rangeN/A
Volume41
Open interest3.11k
  • Bloomberg

    Covid Vaccine Maker Novavax Tumbles After Cutting Annual Sales Forecast 50%

    (Bloomberg) -- Novavax Inc. shares had their biggest loss in more than three years as the drugmaker slashed its 2022 revenue forecast late Monday on disappointing demand for its Covid-19 vaccine that trailed competitors getting to market.Sales for the year will be as much as $2.3 billion, less than half the previous expected peak of $5 billion, the company said in a statement. Novavax also reported a second-quarter loss of $6.53 a share, wider than analysts’ average estimate of $5.24. The Gaithe

  • Financial Times

    Pfizer tests vaccine to fend off spread of tick-borne Lyme disease

    US drugmaker and French partner begin late-stage trial with 14% of global population showing evidence of infection

  • Business Wire

    Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

    NEW YORK & SAINT-HERBLAIN, France, August 08, 2022--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15.